Continuing the Cause; Humane Global Animal Welfare

Q: What were InVitro International (IVRO) Q2 FY26 sales and net income reported May 5, 2026?

Q2 FY26 sales were $206,840 and Q2 net income was $17,556 . According to the company, sales rose 5.3% year-over-year while net income increased 14.7% versus Q2 last year, with management citing improvement versus 1Q FY26.

Q: How do InVitro (IVRO) year-to-date sales for FY26 compare to FY25 first half?

YTD FY26 sales were $389,440 , 11.6% below the comparable first half of FY25. According to the company, the first-half sales shortfall contrasts with quarterly improvement seen in Q2 versus prior-year Q2.

Q: What does InVitro say about profitability goals after the FY26 Q2 report?

InVitro is aiming for its 21st consecutive year of profitability . According to the company, management reported Q2 improvements over 1Q and continues a strategic shift while pursuing global regulatory acceptance of in vitro test results.

Q: How did InVitro's half-year net income change in FY26 versus last year?

Half‑year net income declined by 42.8% versus last fiscal first half. According to the company, that large year-over-year drop contrasts with a Q2 net income gain and reflects the combined results for the first two quarters.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported FY'26 Q2 sales of $206,840, up 5.3% year-over-year, and Q2 net income of $17,556, a 14.7% increase versus Q2 last year. Year-to-date sales are $389,440, 11.6% below the comparable first half of FY'25, while half‑year net income is 42.8% below last fiscal first half. Management said Q2 improved versus 1Q '26 and reiterated a goal of a 21st consecutive year of profitability while pursuing a new strategic direction and global regulatory acceptance of in vitro test results.

Positive

Q2 net income +14.7% (Q2 FY26: $17,556)

Negative

Half-year net income −42.8% versus prior fiscal first half
YTD sales −11.6% versus first half FY25 (YTD $389,440)

05/05/2026 - 09:00 AM

Placentia, California--(Newsfile Corp. - May 5, 2026) - Today, InVitro International (OTCQB: IVRO) reported FY '26 Q2 sales of $206,840, up 5.3 % over the same period in FY '25. YTD sales of $389,440 are now 11.6% below half FY '25. FY '25 Q2 net income of $17,556 was 14.7% ahead of Q2 last year. Half year '26 net is 42.8 % below last FY first half.

CEO & Chairman, W. Richard Ulmer observed: Our second quarter financials were brighter than 1Q '26; they advanced over last year in both sales and net income. InVitro is aiming for its 21^st consecutive year of profitability while also making progress in its new strategic direction. We continue to find prospects globally who are just learning of regulatory policies changing toward acceptance of in vitro test results. The future remains bright and more encouraging than ever."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company's testing technologies are designed to produce Regulatory Agencies' approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update such statements.

Company Contact:
W. Richard Ulmer
Chairman and Chief Executive Officer
(800)246-8487
invitro@invitrointl.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295850

FAQ

What were InVitro International (IVRO) Q2 FY26 sales and net income reported May 5, 2026?

Q2 FY26 sales were $206,840 and Q2 net income was $17,556. According to the company, sales rose 5.3% year-over-year while net income increased 14.7% versus Q2 last year, with management citing improvement versus 1Q FY26.

How do InVitro (IVRO) year-to-date sales for FY26 compare to FY25 first half?

YTD FY26 sales were $389,440, 11.6% below the comparable first half of FY25. According to the company, the first-half sales shortfall contrasts with quarterly improvement seen in Q2 versus prior-year Q2.

What does InVitro say about profitability goals after the FY26 Q2 report?

InVitro is aiming for its 21st consecutive year of profitability. According to the company, management reported Q2 improvements over 1Q and continues a strategic shift while pursuing global regulatory acceptance of in vitro test results.

How did InVitro's half-year net income change in FY26 versus last year?

Half‑year net income declined by 42.8% versus last fiscal first half. According to the company, that large year-over-year drop contrasts with a Q2 net income gain and reflects the combined results for the first two quarters.

Did InVitro (IVRO) report any operational outlook or strategic progress in the May 5, 2026 release?

The company reported ongoing strategic adjustments and progress toward broader regulatory acceptance of in vitro tests. According to the company, these efforts accompany a focus on sustaining profitability while expanding global prospects.